The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05070091

Acronym

ENDO-COVID19

Enrollment

180

Registered

2021-10-06

Start date

2021-01-26

Completion date

2021-12-01

Last updated

2022-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Insufficiency, COVID-19, Hyperthyroidism, Hypothyroidism, Low Triiodothyronine Syndrome, Subacute Thyroiditis

Keywords

COVID-19, thyroid, adrenal gland, pituitary, glucocorticoids

Brief summary

The main focus of the study is the assessment of hormonal function in the course of COVID-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* PCR-confirmed COVID-19 infection * volunteers consenting to participate

Exclusion criteria

* no consent

Design outcomes

Primary

Measure	Time frame	Description
Meeting the primary endpoint criteria.	Time of hospitalization, typically less than one month.	Primary endpoint is defined as a composite endpoint including death, mechanical ventilation, vasopressor use, noninvasive ventilation, prolonged hospital stay (\>10 days).

Countries

Poland

Outcome results